ArticleImmunity2017
CTLA-4
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.Viruses · 2022Pooled it
- Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Upregulation of cellular exhaustion-related genes and CD4 + T cell disturbances in immunological non-responders on antiretroviral therapy.Immunologic research · 2026Article
- The immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Phenotypic analysis of productively SIV-infected cells in blood and lymphoid tissues of rhesus macaques.Cell reports · 2026Article
- HIV tri-specific killer engagers directly enhance NK cell function and safely expand NK cells in vivo.Cell reports. Medicine · 2026Article
- Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4Nature communications · 2026Article
- HIV-1 infection does not confer intrinsic resistance to cell death induced by cytotoxic T lymphocytes.bioRxiv : the preprint server for biology · 2026Article
- Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence.Current HIV/AIDS reports · 2026Review
- Persistent activation of monocytes/macrophages and cell senescence in SIV-infected macaques on ART.Frontiers in immunology · 2026Article
- Effective and safe use of immune checkpoint inhibitors for non-small cell lung cancer in people living with HIV.HIV medicine · 2025Review
- Persistent Activation of Monocytes/Macrophages and Cell Senescence in SIV-Infected Macaques on ART.bioRxiv : the preprint server for biology · 2025Article
- Transient tissue residency and lymphatic egress define human CD56Nature immunology · 2025Article
- Therapeutic CD8Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques.Journal of virology · 2025Article
- Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques.Infectious disease reports · 2025Review
- IL-21 and anti-α4β7 dual therapy during ART promotes immunological and microbiome responses in SIV-infected macaques.JCI insight · 2025Article
- Anatomical, subset, and HIV-dependent expression of viral sensors and restriction factors.Cell reports · 2025Article
- Rapid systemic spread and minimal immune responses following SIVsab intrarectal transmission in African green monkeys.JCI insight · 2024Article
- Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption.Nature immunology · 2024Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Colleen S McGaryDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Justin HarperDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Luca MicciDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Susan P RibeiroDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Sara PaganiniDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Leticia Kuri-CervantesDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Clarisse BenneDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Emily S RyanDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Robert BalderasBecton Dickinson Immunosciences, San Jose, CA 95131, USA.
Sherrie JeanDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Kirk EasleyDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Atlanta, GA 30329, USA.
Vincent MarconiDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA.
Guido SilvestriDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA.
Jacob D EstesAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Rafick-Pierre SekalyDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Mirko PaiardiniDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA. Electronic address: mirko.paiardini@emory.edu.
Emory University · USCase Western Reserve University · USLeidos (United States) · USBecton Dickinson (United States) · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0MCentral memory CD4 T cell infection: key role in ART response and HIV persistenceR01AI110334 · NIAID · EMORY UNIVERSITY · PI MARCONI, VINCENT CHARLES, PAIARDINI, MIRKO · 2013 to 2017
$4.4MImmune based interventions for HIV eradicationR01AI116379 · NIAID · EMORY UNIVERSITY · PI PAIARDINI, MIRKO · 2015 to 2019
$4.2MPersistent Virus Reservoirs in SIV-infected MacaquesR33AI104278 · NIAID · EMORY UNIVERSITY · PI PAIARDINI, MIRKO · 2015 to 2017
$1.6MTargeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.R33AI116171 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL, PAIARDINI, MIRKO · 2016 to 2018
$1.5MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI110334NIAID NIH HHS R01 AI116379NIAID NIH HHS R33 AI104278NIAID NIH HHS R33 AI116171NIH HHS P51 OD011132
Abstract
Antiretroviral therapy (ART) suppresses viral replication in HIV-infected individuals but does not eliminate the reservoir of latently infected cells. Recent work identified PD-1
Indexed as
AnimalsAnti-Retroviral AgentsCD4-Positive T-LymphocytesCTLA-4 AntigenHIV-1HIV InfectionsHost-Pathogen InteractionsHumansImmunologic MemoryIn Situ HybridizationLymph NodesMacaca mulattaMicroscopy, ConfocalProgrammed Cell Death 1 ReceptorSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnti-Retroviral AgentsCTLA-4 AntigenProgrammed Cell Death 1 Receptoranimal modelsco-inhibitory receptorsCTLA-4HIVlatent viral reservoirPD-1regulatory T cellsSIVT follicular helper cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.